Raymond James downgrades EverQuote stock rating as growth expected to slow

Raymond James downgraded EverQuote (NASDAQ:EVER) from Strong Buy to Outperform, reducing its price target to $30 from $35, citing anticipated revenue growth deceleration post-Q3 2025 and a slower pace of adjusted EBITDA margin expansion after fiscal year 2025. This forward-looking adjustment comes despite EverQuote's robust Q2 2025 financial results, which included a 34% year-over-year revenue increase and record net income, and the stock's significant 28% year-to-date outperformance against the S&P 500. JPMorgan also slightly lowered its price target to $29 while maintaining an Overweight rating, noting potential tariff impacts on future margins.

Analysis

EverQuote (NASDAQ:EVER) is facing a disconnect between its robust recent performance and a more cautious forward-looking analyst outlook. Raymond James has downgraded the stock from Strong Buy to Outperform and reduced its price target to $30 from $35, citing expectations of a material deceleration in revenue growth post-Q3 2025. The firm projects growth will moderate to a high single-digit rate by FY27, falling below management targets, with adjusted EBITDA margin expansion also set to slow after FY25. This cautious stance is notable given the company's strong Q2 2025 results, which included a 34% year-over-year revenue increase to $156.6 million and a record net income of $14.7 million. Furthermore, the stock has significantly outperformed, gaining 28% year-to-date, and currently trades at an 11% premium to its 200-day moving average. This sentiment of tempered expectations is echoed by JPMorgan, which, while maintaining an Overweight rating, trimmed its price target to $29 due to concerns about potential tariff impacts on second-half margins and noted that Q2 revenues only met, rather than beat, expectations. The company's fundamentals remain strong, with more cash than debt, and a recent discounted $21 million share repurchase from its Chairman signals insider confidence.

Key Decisions for Investors

• Given the stock's 28% year-to-date outperformance and the valuation premium, investors might consider trimming positions to crystallize gains amid emerging concerns over future growth deceleration.
• Prospective investors should weigh the company's strong balance sheet and recent 34% revenue growth against the analyst consensus that growth is peaking and margin pressure from factors like tariffs is a risk.
• Monitor upcoming quarterly reports closely for any confirmation of the projected revenue slowdown and pay specific attention to management's guidance on margin trajectory for the second half of the year.
• The recent discounted share buyback from the Chairman could be viewed as a positive signal of intrinsic value, but this should be balanced against the multiple analyst price target reductions.